Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/02/13 | Initial statement of beneficial ownership of securities |
|
3 | ||
| 12/02/13 | Initial statement of beneficial ownership of securities |
|
3 | ||
| 11/26/13 | Current report filing |
|
14 | ||
| 11/20/13 | Current report filing |
|
3 | ||
| 11/14/13 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
38 | |
| 10/25/13 | Current report filing |
|
2 | ||
| 10/10/13 | Definitive proxy statements |
|
259 | ||
| 10/08/13 | SEC-generated letter |
|
2 | ||
| 10/07/13 | SEC-generated letter |
|
1 | ||
| 10/04/13 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 |